Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14052
Abstract: Previous studies reported the efficacy and safety profile of extended half‐life PEGylated recombinant factor VIII (FVIII) rurioctocog alfa pegol (TAK‐660, SHP660, BAX 855) in preventing bleeding in haemophilia A patients. read more here.
Keywords: long term; safety; alfa pegol; haemophilia long ... See more keywords
Long‐term joint outcomes in adolescents with moderate or severe haemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14636
Abstract: Favourable joint outcomes are expected with modern haemophilia A (HA) management. Evaluation of long‐term treatment outcomes is hampered by the delay between bleeding episodes during childhood and resulting joint outcomes in adulthood. read more here.
Keywords: term joint; long term; haemophilia long; joint outcomes ... See more keywords